Carl Icahn Loses Proxy Battle At Biogen Idec (BIIB)-WSJ
More News related to BIIB
- Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
- Biogen Idec to Present at the 3rd Annual CITI Biotech Day
- Morgan Stanley Starts Elan (ELN) at Overweight
- Biogen Idec to Present at the Thomas Weisel Partners Healthcare Conference
- Deutsche Bank Notes Tysabri PML Patients are Recovering (BIIB, ELN)
More News related to Corporate News
- GM Said Rumors of a Government Bailout is a 'Myth'
- Morgan Stanley Says Slide in Ag Names 'Unfounded' (POT, MOS, AGU, CF, IPI)
- Atticus Capital Defends Itself After Hedge Fund Liquidation Rumor
- Plunge In Spectranetics (SPNC) Related to Federal Raid
- Reports Lehman (LEH) May Spin-Off $32B To 'Bad Bank'
Carl Icahn Loses Proxy Battle At Biogen Idec (Nasdaq: BIIB).
Related Categories
Corporate NewsStocks Mentioned
+0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
